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Herpes simplex viruses (HSV) ~ are the causative agents of cold sores, enceph- 
alitis, and eye and genital infections (1). A series of glycoproteins designated gB, 
gC, gD, and gE (2) have been  identified as structural components of the HSV 
virion envelope and implicated in virus-induced alterations of mammalian cells 
(3).  These  glycoproteins are  expressed  on  the plasma  membranes of infected 
cells,  and act as major antigenic stimuli for the cellular and humoral responses 
of the host (4). It is pertinent to the development of a subunit vaccine effective 
in controlling primary HSV infection to understand the role of these individual 
glycoproteins in the induction of the various components of immune reactivity. 
Most of the recent effort in vaccination against HSV infection has been concen- 
trated on glycoprotein D  (gD),  culminating in cloning of the gD gene (5) and 
synthesis  of peptides  corresponding  to  the  neutralization  epitopes  (6).  The 
importance of gD is based largely on its ability to induce neutralizing antibody 
(7-9) and its crossreactivity between type I and type II HSV (10-13).  However, 
since  it  has  been  repeatedly demonstrated (14-22)  that  recovery from  HSV 
infections involves both humoral and cell-mediated immunity, other glycopro- 
reins, which do not induce neutralizing antibodies, may be strongly protective 
via a different mechanism. 
In this paper,  we first compared the ability of monoclonal antibodies (mAb) 
directed against different individual glycoproteins to protect susceptible mice 
against lethal HSV-I challenge. Secondly, glycoproteins immunopurified by mAb 
were examined for protective capacity, and the immunological mechanism un- 
derlying the protection was analyzed. Our data show that a  1 15 kilodaltons (kD) 
glycoprotein (gB), though not possessing epitopes for inducing virus-neutralizing 
antibodies, contains antigenic determinants capable of activating T  cells that are 
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responsible  for the glycoprotein's prophylactic potential.  These  L3T4  ÷ T  cells 
adoptively  protect  mice  against  lethal  HSV  infection,  probably  via  a  linked- 
recognition effect, the  115 kD glycoprotein acting as a  potent carrier for virus- 
neutralizing epitopes on the whole virus, upon infectious challenge. 
Materials and Methods 
Mice.  CBA mice were bred at The Imperial Cancer Research Fund colony in Mill Hill, 
London, and at The Wellcome Research Laboratories, Beckenham, Kent. 
Cells.  BHK-21/C 13 cells were maintained in monolayer cultures in Dulbecco's Eagle's 
medium (DEM)  containing  10%  calf serum.  Vero cells  (African green  monkey kidney 
cells) were grown in RPMI 1640 medium containing 10% fetal calf serum. 
Virus.  HSV type I  Krueger strain  (HSV/PI) was obtained from Beecham Research 
Laboratories, Brockham Park, Betchworth, United Kingdom. Virus stocks were prepared 
from BHK cells infected at a multiplicity of infection (m.o.i.) of 0.1 plaque-forming units 
(pfu)/cell. This was increased to 20 pfu/cell to produce viral glycoproteins. The virus was 
allowed to absorb at 37 °C for 1 h, cells were washed twice and incubation was continued 
in  fresh  medium  for  2 d  (virus  stock)  or  18 h  (viral  glycoproteins).  Complete  HSV-I 
particles were purified as previously described (24).  Viruses were inactivated by heating 
at 56°C for 1 h. 
Antibodies.  Hybrid lines  TI57,  G8D1,  and  C2D2  were  produced as  previously de- 
scribed; they have been previously characterized (25-27). Polyclonal sera were raised by 
injecting CBA mice intraperitoneally with  either 5 X  106 pfu of heat-inactivated HSV-I 
or  10 ug of the  115 kD glycoprotein in  saline,  at weekly intervals.  5 d  after the  third 
injection,  mice were bled, and the sera  were pooled.  Ig fractions of mAb from ascites 
fluid  were  purified  on  a  protein  A-Sepharose CL  4  B  column.  Monoclonal  Ig were 
coupled to Sepharose CL 4 B using sodium metaperiodate activation (28). 
Immunopurification.  Purification of viral  glycoproteins was performed by a modifica- 
tion of the procedure of Secher and Burke (29), as was previously described (24). Briefly, 
cells were harvested and disrupted by ultrasonication in  E buffer (1%  Nonidet P-40 in 
150  mM  sodium  chloride,  2  mM  EDTA,  25  mM  Tris  HC1  buffer  pH  8.0,  1  mM 
phenylmethyl sulphonyl fluoride). After centrifugation at  100,000 g for 1 h at 4°C, the 
extract was applied to the mAb-Sepharose column, sequentially washed with (a) phosphate- 
buffered saline  (PBS); (b) 25 mM Tris HCI, pH 8.0, 50 mM NaCI, 0.5%  Nonidet P-40, 
and 0.5% sodium deoxycholate; (c) 50 mM Tris HCI, pH 6.8; and (d) 9 M ethanediol, 0.3 
M  NaCI, and 0.0075  M sodium phosphate buffer, pH  7.4.  Elution of the glycoproteins 
was achieved at pH 3.0 with 9 M ethanediol, 0.3 M NaCl, and 0.1  M citric acid. 
RadiolabeUing and lmmunoprecipitation.  Monolayer cultures of BHK 21/C 13 cells were 
infected with HSV-I at an  m.o.i, of 20 pfu/cell, and the cells were radiolabelled at 5 h 
postinfection for 24 h with L-[3~S]methionine (Amersham International, Ltd., Amersham, 
England; sp act, >600 Ci/mmol) at  50 #Ci/ml  in  DEM  containing one-fifth its  normal 
concentration of methionine. Cell extracts were harvested, washed, and solubilized  in E 
buffer,  clarified  by  centrifugation,  and  used  for  immunoprecipitation  with  the  mAb. 
Immune complexes were collected with  Cowan A strain of Staphylococcus aureus,  repeat- 
edly washed in 1% Nonidet P-40, 650 mM NaCl, 1 mM EDTA, 10 mM Tris HCI buffer, 
pH 7.5, containing 10% sucrose, reduced, and electrophoresed in a  12.5% acrylamide gel 
crosslinked  with  N,N'-diallytartardiamide  (30).  Gels  were  processed  as  described  by 
Bonner and Laskey (31),  then exposed to Kodak X-omat AR x-ray film at -70°C. 
Immunization and Infection of Mice.  Young adult CBA mice were injected subcutane- 
ously in four sites in the flanks  with a total of 30 #g of immunopurified glycoprotein in 
saline  or 5 ×  106 pfu heat-inactivated HSV-I in saline,  or saline alone. 7 d after immuni- 
zation mice were infected with  10 x  LDs0 (50% lethal  dose) HSV-I, either 200 #l i.p.  or 
with 20 ul in  the left footpad. Disease  symptoms and mortality were recorded daily.  In 
our experience, the susceptibility  of mice is highly sensitive  to factors such as sex,  age, 
and ambient temperature. It is essential  that the LDs0 dose be accurately titrated for each 
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Induction  and Determination of Delayed-type Hypersensitivity (DTH) Response.  Mice were 
immunized intradermally with  10 ~g of purified, heat-inactivated HSV-I or the glycopro- 
reins 2 d  after receiving  150  mg/kg body weight of cyclophosphamide (Cy) intraperito- 
neally. 5 d after sensitization, they were tested for DTH with injections of antigen (5 gg) 
into the right hind footpad. An equal volume (50 tA) of saline was injected into the left 
hind  footpad.  Footpad  swelling  was  measured  24  and  48 h  after  injection.  DTH  was 
expressed as the difference in thickness of right vs. left hind footpad in 10  -2 mm. 
Fractionation and Adoptive Transfer of Cells.  Spleen and lymph node (inguinal, brachial, 
axillary, and mesenteric) cells were harvested from normal mice or mice injected subcu- 
taneously in four sites with the  l 15 kD glycoprotein in saline 7 d before cell harvest. The 
cells were collected in  PBS, and  sedimented  by centrifugation.  Half of the  pooled cell 
population was depleted of B cells by fractionation on an anti-Ig column, as previously 
described (32). The resulting cell preparations contained <0.5% Ig  + cells as estimated by 
anti-lg fluorescence staining. The other half of the pooled cells were depleted of L3T4 + 
T  cells by resuspending  10 s cells in  1 ml of neat spent supernatant of mAb clone, GK 1.5 
(33).  After  incubation  for  1 h  at  room  temperature,  the  cells  were  sedimented  by 
centrifugation,  and  resuspended  in  2  ml of a  1:10 dilution  of complement (Low-tox-M 
rabbit complement; Cedarlane  Laboratories  Ltd.,  Hornby, Ontario,  Canada),  and incu- 
bated  for an additional  45  min  at  37°C.  At the  end  of the  incubation,  the  cells  were 
washed twice, and their viability was estimated by trypan blue exclusion. Graded numbers 
of viable  cells  were  injected  intravenously into syngeneic recipients  that  were  infected 
24 h later with an intraperitoneal  injection of 10 ×  LDs0 of HSV-I. 
Virus Neutralization.  Virus (~200  pfu) diluted  in  RPMI  1640 containing  10%  heat- 
inactivated fetal calf serum was incubated with heat-inactivated antiserum for 1 h at 37°C, 
with  or  without  complement.  Residual  viral  infectivity,  relative  to  that  treated  with  a 
control preimmune serum, was determined by plaque assay using vero cells. 
Radioimmunoassay  (RIA) for  Viral-specific Antibodies.  HSV-I-specific antibody  in  the 
serum  was assayed by a  solid-phase  RIA. All assays were set up in duplicate.  Dynatech 
(Cambridge, MA) U-bottom flexiplates were coated with purified, heat-inactivated HSV- 
I (50 ug/ml,  50 ul/well) and 50/~1 dilution of serum was added and incubated for 1 h at 
37°C.  After  washing,  50  #]  of  ~25I-labelled,  affinity-purified  rabbit  anti-mouse  IgG 
was added and incubated overnight at 4°C. For antibody isotype determination,  50 ul of 
a  1:100 dilution of rabbit anti-mouse  Ig isotype serum (Miles Laboratories,  Naperville, 
IL) was added as second layer.  After washing,  ~SI-labelled,  affinity-purified goat anti- 
rabbit  antibody was added,  and  incubated  overnight at  4°C.  After  extensive  washing, 
each well was counted in a gamma counter. Endpoints were taken as the highest dilutions 
with twice the cpm of the corresponding samples from control normal mice. 
Proliferation Assay.  All assays were set up in 96-well flat-bottom tissue culture plates. 
Triplicate cultures of 250 #l medium (RPMI  1640 containing 10% heat-inactivated fetal 
calf serum,  2 mM L-glutamine,  10 mM Hepes and 5 x  10  -5 M  2-mercaptoethanol)were 
set up as previously described (34). Briefly, irradiated normal spleen adherent cells were 
plated in medium containing 5 x  105 pfu/ml of inactivated HSV-I, and incubated in an 
atmosphere of 6% COz at 37°C. After 4-6 h, 2 x  105 primed lymph node T  cells were 
added.  96 h  thereafter,  cultures  were  pulsed  for  6 h  with  1  #Ci  (37  mBq)  ~25I-UdR. 
Results  were expressed  as mean  +  SD.  As a  source of primed  T  cells,  popliteal  lymph 
node cells were obtained from CBA mice 10-15 d after footpad injection of 5 ×  10  6 pfu 
of inactivated HSV-I or 25 ~g of immunopurified glycoprotein emulsified with an equal 
volume of Freund's  complete adjuvant.  Cell  suspensions  were prepared  by teasing the 
tissue through a sterile nylon mesh, and were enriched for T  cells by incubation on nylon 
wool.  Antigen-presenting  cells  were  spleen-adherent  cells  prepared  from normal  CBA 
mice by plating  spleen  cells  on  plastic  petri  dishes.  After  2 h,  nonadherent  cells  were 
washed away, and the adherent  cells were recovered by treating  the plates with  3  mM 
EDTA for  15  min at  37°C. The cells were irradiated  with  1,000 tad before use in the 
assay. 
Statistical Analysis.  Significances of the results were analysed by Student's t test; p  < 
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Results 
Characterization ofmAb.  Three hybridoma cell lines producing mAb to  the 
envelope glycoproteins of HSV-I  were established as described previously (25, 
26). Fluorographs of radioimmune precipitates carried out with [35S]methionine- 
labelled extracts  from  infected or mock-infected baby  hamster  kidney (BHK) 
cells, and electrophoretically separated on N,N'-diallytartardiamide crosslinked 
gels  revealed three different glycoproteins of apparent  molecular masses  103 
(G8D1),  63  (C2D2),  and  115  kD  (TI57),  as  shown  in  Fig.  1,  and  they  are 
designated gH,  gD, and gB,  respectively. The  103  kD (G8D1) was previously 
designated 123 kD (25). However, due to current confusion in HSV glycoprotein 
terminology, we prefer to refer to the detected glycoprotein species as 103,  63, 
and  115  kD glycoproteins, respectively, mAb in culture supernatant were iso- 
typed using rabbit  anti-mouse  Ig isotype-specific antisera, and they belong to 
IgG2a (G8D1), IgM (C2D2), or IgG2b (TI57) (Table I). Experiments performed 
to test the capacity of ascitic fluid of the three mAb to neutralize HSV-I in the 
absence of complement indicate that only C2D2 antibodies neutralize and had a 
relatively high neutralizing titer (>250; data not shown). Both G8D1 and C2D2 
can neutralize HSV-I in the presence of complement, and the titer is >1,280.  In 
FIGURE  1.  Autoradiograms of sodium dodecyl sulfate-polyacrylamide gel electrophoresis of 
HSV glycoproteins specifically precipitated  by  mAb.  Constant  amounts  of [sSS]methionine- 
labelled, HSV-l-infected BHK cells were preincubated with Ig from ascites fluid or hybridoma 
cell supernatant, and the immune complexes were collected with Cowan A strain orS.  aureus. 
Immune-precipitated proteins were electrophoresed under  reducing conditions on a  12.5% 
sodium dodecyl sulfate-polyacrylamide gel crosslinked with N,N'-diallytartardiamide, as de- 
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TABLE  I 
Passive Protection of mAb to HSV-I Glycoproteins 
Glycoprotein  Neutralizing  Survivors (day 
mAb isotype  (kD)  titer*  21) 
G8D1 (G2a)  103  >1,280  20/20 
C2D2 (M)  63  >1,280  19/20 
T157 (G2b)  115  <40  0/10 
Normal mouse serum  --  <40  2/20 
Groups of mice were injected in the hind footpads with  10 x  LDs0 of 
HSV-I (Krueger strain, HSV/P 1) and 24 h later with 0.3 ml i.p. ofascitic 
fluid containing the mAb or normal mouse serum. They were observed 
daily for disease symptoms and mortality until 21 d postinfection. Similar 
results were obtained when the viruses were administered intraperito- 
neally. 
* Reciprocal dilutions of 50% neutralization of infective virus by antibody 
in the presence of complement. 
contrast, mAb TI57 has no detectable neutralizing activity, even in the presence 
of complement (Table I). 
Effect of Passively Transferred mab on Host Resistance to HSV-I Infection.  It has 
been shown previously (35,  36)  that passive transfer of mAb directed against 
virion envelope glycoproteins protected mice from a lethal challenge with HSV-I. 
It was also reported that the capacity of g]ycoprotein-specific mAb to neutralize 
HVS-I,  to  promote  complement mediated cell  lysis  and  antibody dependent 
cellular cytotoxicity (ADCC) in vitro did not correlate with the protective activity 
of antibody in vivo (37). In fact, one monoclonal antibody devoid of all the three 
immunologic reactions in vitro was highly effective in promoting recovery from 
HSV-I induced ocular disease (37). Therefore, we tested the capacity of all three 
mAb to protect susceptible mice from HSV-I infection, using a standard protocol 
(25, 35). Ascitic fluid (0.3 ml) was injected intraperitoneally into nine 9-wk-old 
male CBA mice 24 h after footpad or intraperitoneal infection with  10 X LDs0 
HSV-I.  Mice  injected with  mAb G8D1  or  C2D2  were completely protected 
against the HSV-I infection, whereas antibody TI57 was ineffective in conferring 
passive protection (Table I). Such ineffectiveness was not improved by increasing 
the amounts of ascitic fluid transferred to 0.6 ml (data not shown). 
These results are in agreement with previous reports (35) that  neutralizing 
mAb against the type-common epitope of gD and the type-specific epitope of gC 
were protective when given after subcutaneous virus infection. They also dem- 
onstrated a good correlation between neutralizing activity and protective capacity 
of antibodies specific for glycoproteins. 
Protective  Effects of Immunopurified  Glycoproteins.  The demonstration of pas- 
sive protection clearly indicates that individual viral glycoproteins are important 
and  vary in  the  generation  of protective  immunity.  Differences in  biological 
activities of mAb in vivo may be related to the topographical location or temporal 
expression of viral glycoprotein epitopes on the surface of infected cells, to which 
a particular mAb binds. Therefore, it was of interest to compare the effectiveness 
of the three immunopurified glycoproteins in inducing immune responses capa- 
ble of interfering with HSV-I infection in vivo. Mice were immunized subcuta- 
neously with  30 #g of the glycoproteins in saline.  Control  mice were injected CHAN  ET  AL.  1309 
TABLE  II 
Protective Immunity and Antibodies Induced by Immunopurified 
HSV-1 Glycoproteins 
Glycoproteins  Survivors 
Antibody titer (RIA) 
Prechallenge  Postchallenge 
103 kD  4/8  20  20 
63 kD  3/8  20  2O 
115 kD  8/8  320  2,560 
Inactivated HSV-1  8/8  320  5,120 
Saline  1/8  <20  <20 
Groups of mice were injected with 30 #g s.c. glycoprotein in saline or 5 X 
106 heat-inactivated HSV-I. They were bled (prechallenge sera) 6 d later, 
and challenged in the footpad with 10 x LDs0 of HSV-124 h thereafter. 
All  mice were  bled again  3 d  after challenge (postchallenge sera) and 
mortality recorded until 21 d after infection. 
TABLE III 
Analysis of  Antibody lsotypes Induced by Injection of  HSV-I and Immunopurified 
115 kD Glycoprotein 
Antibody iso-  Inactivated HSV-I  115 kD glycoprotein 
type  Prechallenge  Postchallenge  Prechallenge  Postchallenge 
A  <10  160  <10  80 
M  320  2,560  320  2,560 
Gi  <10  320  <10  160 
G2a  <10  <10  <10  10 
G2b  <10  320  <10  160 
G3  80  320  80  320 
Same serum samples as those described in Table II. 
with saline or 5  ×  10  6  pfu of heat-killed HSV-I, also diluted in saline.  7 d  later, 
all animals were challenged in the footpad with  10 x  LDs0 dose of live virus. 
Mice  immunized  with  heat-killed  virus  and  the  1 15  kD  glycoprotein  were 
completely protected  while  103  and  63  kD glycoproteins  induced  only partial 
protection  (Table  II).  We  therefore  attempted  to  analyze  the  immunological 
mechanisms  underlying  the  effectiveness of  1 15  kD  glycoprotein  as a  subunit 
HSV-I vaccine. 
Antibody  Response  and  Protection.  Although  TI57  was  neither  neutralizing 
nor passively protective, it is possible that the protective effects of immunopuri- 
fled  1 ! 5  kD  glycoprotein  are  due  to  humoral  antibody  directed  against  other 
epitopes on the same molecule. Antibody titers against HSV-I in mice immunized 
with  the  three  glycoproteins  were  measured  by  RIA.  As  shown  in  Table  II, 
antibody  titers  to  HSV-I  before  infection  and  early postinfection  were  signifi- 
cantly  elevated  only  in  mice  immunized  with  inactivated  virus  or  115  kD 
glycoprotein. Thus, the prophylactic capacity of the  1 15 kD glycoprotein corre- 
lates with an early induction of specific antibody, which is even more evident 3 d 
after virus challenge.  Table III analyzes the isotypes of HSV-specific antibodies 
in  the  serum  of mice induced  by inactivated  HSV or the  1 15  kD  glycoprotein 
before and  after challenge  infection.  There  was remarkable similarity between 1310  HELPER  T  CEL1.S  PROTECT  MICE  AGAINST  HERPES  INFECTION 
TABLE  IV 
Passive Transfer of Polyclonal Antibodies  from Mice Immunized with 
115 kD Glycoprotein 
Neutralizing 
Antigen*  titer*  Survivors§ 
115 kD glycoprotein  <20  0/10 
HSV-1  >640  9/10 
Control (NMS)  <20  0/10 
* Polyclonal ]lyperimmune sera were raised as described in Materials and 
Methods. Control serum was from unimmunized mice (NMS). 
~; Reciprocal dilutions of 50%  neutralization of infective virus by serum 
in the absence of complement. 
Groups of 10 mice were injected with 10 ×  LDs0 of HSV-I  intraperito- 
neally,  and  24  h  later  injected  intraperitoneally  with  0.35  ml  of the 
serum. Mortality was recorded daily up to 21  d after infection. 
the antibody, responses to the two different priming antigens in total antibody 
titers and isotype distribution. IgM was the predominant class of antibody before 
challenge, and remained so even after challenge. IgG3 was detected in relatively 
high levels before and after challenge, while IgG 1, IgG2b, and IgA were evident 
only after infection. IgG2a  was not detected throughout the experiment. It is 
possible, therefore, that the  115  kD glycoprotein stimulates the production of 
high levels of protective early antibody, and that, in this respect, is superior to 
103 or 63 kD glycoproteins in inducing protective immunity. 
To test this possibility, we examined the neutralizing ability and the passive 
protective capacity of the polyclonal hyperimmune antibodies induced by the 
115 kD glycoprotein. Polyclonal anti-115 kD glycoprotein antibodies and control 
anti-HSV-I and normal CBA sera (0.35 ml) were injected intraperitoneally into 
syngeneic recipients 24 h after a lethal intraperitoneal challenge with HSV-I. In 
contrast to the inactivated virus, the 115 kD glycoprotein did not induce antibody 
with substantial  neutralizing activity or protective capacity (Table  IV).  Thus, 
early antibody response alone is probably not responsible for the prophylactic 
effect of the 115 kD glycoprotein. 
DTH Response and Protection.  DTH to HSV-I has been previously (38) shown 
in mice. Conventionally purified glycoproteins, gC and gD, were able to induce 
and elicit DTH response to HSV (21). Mice immunized with gC developed DTH 
reactivity and were protected from lethal challenge with HSV-I. However, serum 
neutralizing or precipitating antibodies were not detected before HSV-I  chal- 
lenge. It was suggested (21) that the protective effect of gC may be ascribed to a 
DTH  response.  We therefore examined the DTH reactivity in animals immu- 
nized with immunopurified glycoproteins. In repeated experiments, where mice 
were immunized with  10-30  #g  of glycoproteins subcutaneously or  intrader- 
really, none of the glycoproteins induced a significant DTH response (data not 
shown). Pretreatment of mice intraperitoneally with cyclophosphamide (Cy) 2 d 
before immunization, however, significantly enhanced the DTH response. Under 
this regimen, the 115 kD glycoprotein was clearly the most efficient glycoprotein 
in the induction of DTH, which was comparable to that induced by the whole 
inactivated HSV-I (Fig.  2). However, in contrast to HSV-I, the 115 kD glycopro- CHAN  ET  AL.  1311 
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FIGURE  2.  DTH and protective immunity induced by purified inactivated HSV-I or specific 
glycoproteins. Groups of five mice were injected intraperitoneally with 150 mg/kg of Cy, and 
2 d  later immunized subcutaneously with  l0/~g of purified heat-inactivated HSV-I or immu- 
nopurified glycoproteins. 5 d after sensitization, and together with control unimmunized mice 
(hatched  columns),  they  were  tested  for  DTH  in  the  footpad  with  5  ug  of the  antigens 
indicated. Separate groups of eight mice were also similarly primed but challenged intraperi- 
toneally  with  10  ×  LDs0  of  HSV-I  5 d  after  sensitization  without  DTH  testing.  DTH  is 
expressed  as  footpad  thickness  increase  (in  10 -e  mm)  24 h  after  injection.  Vertical  bars 
represent SEM. Survivors were recorded daily until 21 d after infection. 
tein under such immunizing conditions was unable to confer effective protection 
against a lethal challenge of HSV-I (Fig. 2). The Cy pretreatment has been shown 
to drastically reduce B cells and suppressor T  cell precursors (39, 40), and none 
of the mice pretreated with Cy produced a significant amount of specific antibody 
before or 7  d  after challenge infection (data not shown).  It thus appears that 
DTH alone induced by 115 kD glycoprotein is insufficient for protection. 
Induction  of Proliferative  T  Cells by the  115 kD  Glycoprotein.  The high early 
postinfection  antibody  response  in  mice  primed  with  115  kD  glycoprotein 
prompted  us  to  investigate  the  possibility  that  this  glycoprotein may contain 
antigenic determinants recognizable by nonneutralizing antibodies, and capable 
of activating  helper  T  cells  that  may  be  responsible  for  the  glycoprotein's 
prophylactic capacity. To  test this,  we first examined the ability of the three 
glycoproteins to induce T  cells that proliferate upon stimulation with inactivated 
HSV-I in vitro. Results shown in Fig. 3 demonstrate that all three glycoproteins 
induced T  cells that show significant proliferation against HSV-I, the efficiency 
of  proliferative  T  cell  induction  being  in  the  order  of  HSV-I  >  115  kD 
>  63  kD >  103  kD.  These results are in striking correspondence with the su- 
perior  protection,  as  well  as  the  ability  to  induce  a  postchallenge  antibody 
response by whole HSV and 115 kD glycoprotein (compare Fig. 3 and Table 1I). 
It appears  that the proliferative T  cells induced by  115  kD glycoprotein may 
have  a  prophylactic  role.  This  possibility  is  further  investigated  in  adoptive 
transfer experiments. 
Adoptive Transfer of Protective  Immunity with T cells from Donor Mice Immunized 
with 115 kD Glycoprotein.  Donor mice were injected subcutaneously with 30 #g 1312  HELPER  T  CELLS  PROTECT  MICE  AGAINST  HERPES  INFECTION 
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cpm 
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--2- 
103kD  63kD  1,15kDHSV--1  -- 
F]GUnE  3.  In  vitro proliferative responses against inactivated HSV-I  of lymph  node  cells 
from  mice  immunized  with  affinity-purified glycoproteins  or  heat-inactivated  HSV-I.  For 
details, see Materials and Methods. 
TABLE  V 
Adoptive Transfer  of Protective Immunity Against HSV-I Infection with L3T4 + T 
Cells from Donor Mice Immunized with 115 kD Glycoprotein 
Number of cells  Postchallenge 
Donor cells  transferred  Survivors*  neutralizing anti- 
body titer* 
Immune, Ig-  6 ×  107  9/10  160 
6 ×  106  7/10  80 
Immune, treated with GK 1.5  6 ×  107  5/10  40 
plus complement  6 ×  106  2/10  <20 
Normal, lg-  6 ×  107  2/10  <20 
Normal, treated with GK 1.5 plus  6 ×  107  1/10  <20 
complement 
* 21 d after infection. 
* 6 d  postchallenge, serum virus-neutralizing antibody titers in the absence of comple- 
ment. 
of 115  kD glycoprotein, and their spleen and lymph node cells were retrieved 
7 d later. The pooled cell populations were either depleted of B cells by passing 
through an anti-Ig column, or depleted of L3T4  + cells by treatment with mAb 
GK 1.5 and complement, as detailed in Materials and Methods. These subpopu- 
lations of cells  were then  transferred intravenously into groups of 15  normal 
CBA mice at either 6 ×  107 or 6 ×  106 cells per recipient, which were subsequently 
challenged with a  lethal intraperitoneal dose of HSV-I  24 h  after cell transfer. 
10 mice per group were observed for mortality while the remaining 5 were bled 
for titration of virus-neutralizing antibody in the serum. The results presented 
in Table  V  show that 6  x  107  and 6  x  106  Ig- (T  cell-enriched) spleen and 
lymph node cells from  115  kD glycoprotein-immunized donors conferred sub- CHAN  ET  AL.  1313 
stantial protection against HSV-! infection (survivors were 9 of l0 and 7 of 10, 
respectively) compared  with  mice  receiving  6  x  107  of Ig-  cells from  normal 
donors (2 of 10 surviving).  Mice injected with 6 x  107 cells treated with GK1.5 
and complement also showed significant  (5 of 10 surviving) protection,  which, 
however, largely  disappeared  when  the cell  dose was reduced to 6  x  106  cells 
per  recipient  (2  of  10  surviving).  These  results  therefore  suggest  that  the 
protective immunity induced by the  115 kD glycoprotein is adoptively transfer- 
able by L3T4 + T  cells and not B cells. The protection seen in the high dose of 
GK1.5 and complement-treated cells could be due to residual L3T4 + cells, which 
titrated  out  at  a  lower  cell  dose.  Table  V  also  shows  that  the  protection  is 
correlated with the induction of neutralizing antibody in the serum of recipients 
upon  challenge  infection.  Thus,  mice receiving  L3T4 + T  cells and  recovered 
from  the  lethal  infection  developed  significant  levels  of  HSV-I-neutralizinp, 
antibody in  their  serum.  In  contrast,  such antibody was not detectable in  se:a 
from similarly challenged mice receiving 6 x  106 immune L3T4- cells or normal 
cells. 
Discussion 
The  finding (20) that  athymic (nu/nu)  mice are  more susceptible than  their 
normal  litter  mates  to  HSV infections  implies  that  T  cell-mediated  responses 
are  essential  for antiviral  immunity.  Such observations are consistent  with  the 
severity of primary  and  recurrent  HSV infection encountered  (41) in  patients 
with  predominantly  T  cell  immunodeficiencies.  Furthermore,  mice  rendered 
wholely antibody deficient by the regular administration  of anti-# antibody from 
birth  (42) were able to recover from an  HSV-I infection  in  the ear.  However, 
such  B  cell-suppressed  animals  developed  higher  incidence  of latency  and  a 
more florid primary infection of the dorsal root ganglia than did controls.  This 
suggests that specific antibody was essential for restricting the spread of HSV to 
the nervous system, a  finding that was confirmed (42) by the passive transfer of 
specific neutralizing  antibody to nude mice. Nonneutralizing antibodies, on the 
other hand,  were ineffective in restricting entry of virus to the nervous system. 
These  reports  emphasize  the  importance  of both  humoral  and  cell-mediated 
immunity in preventing and controlling HSV infections. 
Data reported in this paper confirm the critical role of neutralizing antibodies. 
They also provide direct evidence that antigenic determinants activating T  cells 
are essential, and sometimes more potent in stimulating prophylactic immunity 
than  those  inducing  neutralizing  antibodies.  Thus,  the  115  kD  glycoprotein, 
which lacks antigenic determinants for stimulating virus-neutralizing antibodies, 
can induce stronger prophylactic immunity than  that produced by 63 and  103 
kD glycoproteins,  though  the  latter  glycoproteins  are  good inducers  of virus- 
neutralizing  antibodies.  This  finding  suggests  that  neutralization  and  passive 
protection should not be the sole criteria for selecting mAb for the identification 
and isolation of protective antigens for prophylactic immunization against infec- 
tious diseases. A precedent for this was noted in the experimental malaria system 
(43).  In contrast to the 63 and  103 kD glycoproteins, the  115 kD glycoprotein 
induced strong DTH and proliferative T  cell responses to intact HSV. Further- 
more, the protective immunity was adoptively transferred  with T  cells bearing 1314  HELPER  T  CELLS  PROTECT  MICE  AGAINST  HERPES  INFECTION 
the L3T4 + surface marker, characteristics of helper T  cells. Such transferance 
of protection  was  accompanied by  a  parallel  enhancement of production  of 
neutralizing antibody in protected recipients upon challenge infection (Table V). 
It thus appears  that a  major protective mechanism induced by immunization 
with the  115  kD glycoprotein in this system is the induction of helper T  cells 
that facilitate the production of neutralizing antibody upon infectious challenge 
via a linked-recognition effect; the 115  kD glycoprotein acting as potent carrier 
for enhancing the production of neutralizing antibodies directed against epitopes 
present  elsewhere on  the  intact  virus.  A  similar  linked-recognition effect has 
been demonstrated in the influenza virus system, where T cells from mice primed 
with matrix protein were found to enhance both the serum hemagglutination- 
inhibiting antibody titer (44), and protection (45) upon heterologous challenge 
infection. 
The fact that 6 X  10 7 spleen and lymph node cells treated with mAb GK  1.5 
and complement were still  capable of transferring significant protection raises 
the possible  involvement of other cells in  the protection induced by  115  kD 
glycoprotein. The L3T4- cytotoxic T  cell would be a  natural candidate. How- 
ever,  it  has  been  shown  in  many viral  systems (46)  that  significant  levels  of 
cytotoxic activity were only induced with infectious virus and, in our system, no 
detectable cytotoxic T  cell reactivity was obtained when mice were immunized 
with inactivated HSV or purified glycoproteins (W.  L. Chan and A. A. Czitrom, 
unpublished).  Another possibility  is  the  transferance of immune  B  cells  that 
secrete specific nonneutralizing antibodies involved in ADCC. Although ADCC 
is  highly cytolytic in  vitro,  its  significance in  vivo  remains  to  be  established. 
Furthermore, the fact that monoclonal and polyclonal antibodies against the 115 
kD glycoprotein did not confer significant protection renders the involvement 
of ADCC highly unlikely. Thus, the most straightforward interpretation would 
be that the modest protective effect of GK  1.5  plus complement-treated cells 
was  due  to  the  helper  activity  of residual  T  cells  that  express  fewer  L3T4 
antigens. This is consistent with the low but significant enhancement of neutral- 
izing antibody titers in the recipients upon challenge infection (Table V). Futh- 
ermore, such modest antibody enhancement and protection largely disappeared 
when the number of cells transferred was reduced to 6 x  10 6. 
DTH is a widely used assay for cell-mediated immunity, which is thought to 
reflect pathological processes involved in infectious diseases.  DTH to HSV has 
been demonstrated in seropositive humans (47), guinea pigs (48), and mice (38). 
Strong correlation was obtained between protection and DTH reactivity induced 
by infectious virus (38) or conventionally-purified glycoprotein C  (21),  though 
direct evidence for a protective role of DTH is still lacking. In our system, using 
the three immunopurified glycoproteins, no detectable DTH reactivity could be 
induced unless the mice were pretreated with Cy. Under such conditions, DTH 
induced by  the  115  kD  glycoprotein was comparable to  that  induced by  the 
intact HSV,  but  unlike the latter,  it was unable to confer effective protection 
against  a  lethal  challenge  infection.  These  results  indicate  that  DTH  alone 
induced by the 115 kD glycoprotein is insufficient for protection. 
Although our data suggest the involvement of helper T  cells for neutralizing 
antibody in the protective immunity induced by  115  kD glycoprotein, they do CHAN ET  AL.  1315 
not exclude a similar helper effect for cytotoxic T  cells (49). Major histocompat- 
ibility  complex-matching  shows  that  at  least  two  T  cell  subsets  determine 
resistance  to  HSV  (18),  class  II-restricted  helper cells,  and  class  I-restricted 
cytotoxic T  cells. Thus L3T4 + helper T  cells for effector cytotoxic T  cells may 
conceivably be induced by 115 kD glycoprotein, and adoptively enhance specific 
cytotoxic T  cell reactivity activated by challenge infection, hence reinforcing the 
host's recovery. 
The prophylactic immunity induced by  115  kD glycoprotein is nontrivial. A 
single subcutaneous injection of 10-30  ~g of the glycoprotein in  saline could 
produce complete protection against a  lethal  (10  ×  LDs0)  challenge infection 
administered intraperitoneally or in the footpad (Table II and our unpublished 
data). Further experiments using isolated and structurally defined peptide frag- 
ments of the  115  kD  glycoprotein may localize  specific epitopes and  lead  to 
chemically defined anti-HSV vaccines. 
Summary 
Three herpes simplex virus type I (HSV-I) glycoproteins of apparent molecular 
masses 103, 63, and 115 kD have been purified using virus-specific monoclonal 
antibodies (mAb) G8D1, C2D2, and TI57, respectively. Both G8D1  and C2D2 
neutralize HSV-I in vitro and passively protect CBA mice against HSV-I infection 
in vivo, whereas TI57 is neither neutralizing nor passively protective. However, 
mice given a single subcutaneous injection of 30 ~g 115 kD glycoprotein in saline 
were  completely  protected  against  lethal  challenges  of  HSV-I  administered 
intraperitoneally or in  the footpad  7 d  after immunization.  In  contrast,  mice 
similarly immunized with  103  or 63  kD glycoproteins were only partially pro- 
tected. The prophylactic immunity was correlated with an early induction  of 
specific antibody,  which became even more evident 3 d  after virus challenge. 
There was a remarkable similarity in antibody isotype distribution between the 
responses to 115 kD glycoprotein and to heat-inactivated intact HSV-I. However, 
the prechallenge sera  from  115  kD  glycoprotein hyperimmunized mice were 
again neither virus-neutralizing nor passively protective. All three glycoproteins 
induced only low levels of delayed-type hypersensitivity (DTH). Pretreatment of 
mice with cyclophosphamide significantly enhanced DTH  to  115  kD and  103 
kD  glycoproteins in  the absence  of antibody,  but  failed to  confer significant 
immunity, indicating that DTH alone is insufficient for protection. Splenic and 
lymph node Ig- (B ceil-depleted) cells from mice protectively immunized with 
115 kD glycoprotein could adoptively transfer effective protection and enhance 
a  virus neutralizing antibody response in  normal recipients challenged with  a 
lethal dose of HSV-I. Both the protection and the ability to enhance neutralizing 
antibody were diminished when the cells were treated with mAb GK  1.5  and 
complement. These results therefore demonstrate that the 115 kD glycoprotein, 
though not apparently containing accessible epitopes for the induction of virus- 
neutralizing antibody, possesses determinants capable of activating helper T cells. 
These L3T4 + cells confer strong protective immunity by enhancing protective 
antibody upon challenge infection, probably through associative help. 
Received  for publication 25 June 1985. 1316  HELPER  X  CELLS  PROTECT  MICE AGAINST HERPES INFECTION 
References 
1.  Nahmias, A.J.,J.  Dannenbarger, C. Wickliffe, andJ. Muther.  1980. Clinical aspects 
of infection with herpes simplex viruses 1 and 2. In The human Herpes-viruses, an 
interdisciplinary  perspective.  A. J.  Nahmias,  W.  R.  Dowdle,  and  R.  F.  Schinazi, 
editors. Elsevier/North-Holland, New York. 2-9. 
2.  Spear,  P.  G.  1980.  Herpes viruses. In  Cell Membranes and Viral Envelopes. H. A. 
Blough andJ. M. Tiffany, editors. Academic Press, Inc., New York. 2:709. 
3.  Norrild, B. 1980. Immunochemistry of herpes simplex virus glycoproteins. Curr. Top. 
Microbiol. lmmunol.  90:67. 
4.  Norrild, B., S. L. Shore, and A.J. Nahmias. 1979. Herpes simplex virus glycoproteins: 
participation  of individual  herpes  simplex  virus  type  1  glycoprotein  antigens  in 
immunocytolysis and  their  correlation  with  previously identified  glycopeptides. J. 
ViroL  32:741. 
5.  Watson, R. J., J. H. Weis, J. S. Salstrom, and L. W. Enquist.  1982.  Herpes simplex 
virus  type-1  glycoprotein  D  gene:  nucleotide  sequence  and  expression  in  E.  coll. 
Science (Wash. DC).  218:381. 
6.  Cohen, G. H., B. Dietzschold, M. Ponce De Leon, D. Long, E. Golub, A. Varrichio, 
L.  Pereira,  and  R. J.  Eisenberg.  1983.  Localization and  synthesis of an antigenic 
determinant of herpes simplex virus glycoprotein D that stimulates the production 
of neutralizing antibody. J.  Virol.  49:102. 
7.  Cohen, G. H., M. Ponce de Leon, and C. Nichols. 1972. Isolation of a herpes simplex 
virus-specific  antigenic  fraction  which  stimulates  the  production  of  neutralizing 
antibody.J. Virol.  10:1021. 
8.  Powell, K. L., A. Buchan, C. Sire, and D. H. Watson.  1974. Type-specific protein in 
herpes  simplex  virus  envelope  reacts  with  neutralizing  antibody.  Nature  (Lond.). 
249:360. 
9.  Eisenberg, R.J.,  M.  Ponce de Leon, L. Pereira, D. Long, and G. H. Cohen.  1982. 
Purification  of glycoprotein  gD  of herpes simplex virus types  1 and  2  by use  of 
monoclonal antibody. J. Virol.  41:1099. 
10.  Eisenberg, R.J., M. Ponce de Leon, and G. H. Cohen.  1980. Comparative structural 
analysis of glycoprotein gD of herpes simplex virus types 1 and 2. J. Virol.  35:428. 
11.  Pereira, L., D. V. Dondero, D. Gallo, V. Devlin, andJ. D. Woodie.  1982. Serological 
analysis of herpes simplex virus types  1 and  2  with  monoclonal antibodies. Infect. 
lmmun.  35:363. 
12.  Spear,  P.  G.  1975.  Glycoproteins specified by herpes  simplex virus  type  1:  their 
synthesis, processing, and antigenic relatedness to HSV-2 glycoproteins. IARC (Int. 
Agency Res. Cancer) Sci. Publ.  11:49. 
13.  Eberle,  R.,  and  R. J.  Courtney.  1981.  Assay of type  specific and  type  common 
antibodies  to  herpes  simplex  virus  types  1 and  2  in  human  sera.  Infect.  Immun. 
31:1062. 
14.  Notkins, A. L.  1974.  Immune mechanisms by which the spread of viral infections is 
stopped. Cell.  Immunol.  11:478. 
15.  Oakes, J.  E.  1975.  Role  of cell-mediated  immunity  in  the  resistance  of mice  to 
subcutaneous herpes simplex virus infection. Infect. Immun.  12:166. 
16.  Bloom, B.  R., and B.  R. Zisman.  1975.  T-cell mediated cytotoxicity against herpes 
simplex virus-infected target cells. In Viral Immunology and Immunopathology. A. 
L. Notkins, editor. Academic Press, Inc., New York.  113-126. 
17.  Rager-Zisman, B.,  and A. C. Allison.  1976.  Mechanisms of immunologic resistance 
to herpes simlex virus 1 (HSV-1) infection.J, lmmunol.  116:35. 
18.  Howes, E.  L., W. Taylor, N. A. Mitchison, and E. Simpson.  1979.  MHC matching CHAN  ET  AL.  1317 
shows that at least two T-cell subsets determine resistance to HSV. Nature (Lond.). 
277:67. 
19.  Lawman,  M.  J.  P.,  B.  T.  Rouse,  R. J.  Courmey,  and  R.  D.  Walker.  1980.  Cell 
mediated immunity against  herpes simplex induction  of cytotoxic T  lymphocytes. 
Infect. Immun.  27:133. 
20.  Oakes, J.  E.,  W.  B.  Davis, J.  A.  Taylor, and W.  A.  Weppner.  1980.  Lymphocyte 
reactivity contributes  to protection  conferred  by specific antibody passively trans- 
ferred to berpes simplex virus-infected mice. Infect.  lmmun.  29:642. 
21.  Schrier,  R.  D.,  L.  I.  Pizer,  and J.  W.  Moorhead.  1983.  Type-specific delayed 
hypersensitivity and protective immunity induced  by isolated herpes simplex virus 
glycoprotein. J. Immunol.  130:1413. 
22.  Sethi,  K. K., Y.  Omata, and  K. E. Schneweis.  1983.  Protection of mice from fatal 
herpes simplex virus type I infection by adoptive transfer of cloned virus-specific and 
H-2 restricted cytotoxic T  lymphocytes. J. Gen.  Virol.  64:443. 
23.  Chan,  W.  L., and N.  A.  Mitchison.  1982.  The use of somatic cell  hybrids for the 
production  of  monospecific  viral  antibodies.  In  New  Developments  in  Practical 
Virology. C. R. Howard, editor. Alan R. Liss, Inc., New York.  125-141. 
24.  Talbot, P., and J. D. Almeida.  1977.  Human cytomegalovirus: purification of enve- 
loped and dense bodies. J. Gen.  ViroL  36:345. 
25.  Chan,  W.  L.  1983.  Protective immunization of mice with specific HSV-1 glycopro- 
teins. Immunology.  49:343. 
26.  La Thangue, N. B., and W. L. Chan.  1984. The characterization and purification of 
DNA  binding  proteins  present  within  herpes  simplex  virus  infected  cells  using 
monoclonal antibodies. Arch. Virol.  79:13 
27.  La Thangue, N. B., W. L. Chan, andJ. D. AImeida. 1984. Monoclonal antibodies to 
herpes simplex virus type 1 glycoproteins show that epitope location influences virus 
neutralization. J. Med. Virol.  13:227. 
28.  Wilson,  M.  B.,  and  P.  K.  Nakane.  1976.  The  covalent  coupling  of proteins  to 
periodate-oxidized sephadex: a  new approach to immunoadsorbent preparation. J. 
Immunol. Meth.  12:171. 
29.  Secher,  D.  S.,  and  D.  C.  Burke.  1980.  A  monoclonal  antibody  for  large  scale 
purification of human leukocyte interferon. Nature (Lond.). 285:446. 
30.  Morse, L. S.,  L. Pereira, B. Roizman, and P. A. Schaffer.  1978. Anatomy of herpes 
simplex virus (HSV) DNA. X. Mapping of viral genes by analysis of polypeptides and 
functions specified by HSV-I x  HSV-2 recombinants.J. Virol.  26:389. 
31.  Bonner, W. M., and R. A. Laskey. 1974. A film detection method for tritium-labelled 
proteins and nucleic acids in poiyacrylamide gels. Eur. J. Biochem.  46:83. 
32.  Shand,  F.  L.  1975.  Analysis of immunosuppression generated by graft-vs-host reac- 
tion. I. Suppressor T-cell component studied in vivo.  Immunology.  29:953. 
33.  Dialynas, B.  P.,  Z. S. Quan,  K. A. Wall, A.  Pierres, J. Quintans,  M.  R.  Loken,  M. 
Pierres, and F. W. Fitch.  1983. Characterisation of the murine cell surface molecule, 
designated L3T4, identified by monoclonal antibody GK 1.5: similarity of L3T4 to 
the human Leu-3/T4 molecule. J. lmmunol.  131:2445. 
34.  Lukic,  M.  L., and N.  A.  Mitchison.  1984.  Self- and allo-specific suppressor T  cells 
evoked by intravenous injection of F protein. Eur. J. lmmunol.  14:766. 
35.  Dix, R. D., L. Pereira, andJ. R. Baringer. 1981. Use ofmonoclonal antibody directed 
against herpes simplex virus glycoproteins to protect mice against acute virus-induced 
neurological disease. Infect. lmmun.  34:192. 
36.  Balachandran,  N.,  S.  Bacchetti,  and  W.  E.  Rawls.  1982.  Protection  against  lethal 
challenge  of  BALB/c  mice  by  passive  transfer  of monoclonal  antibodies  to  five 
glycoproteins of herpes simplex virus type 2. Infect. lmmun.  37:1132. 1318  HELPER  T  CELLS PROTECT  MICE AGAINST HERPES INFECTION 
37.  Rector, J. T., R. N. Lausch, andJ. E. Oakes. 1982. Use of monoclonal antibodies for 
analysis  of antibody-dependent  immunity  to  ocular  herpes  simplex  virus  type  1 
infection. Infect.  Immun.  38:168. 
38.  Nash, A. A., H.J.  Field, and R. Quartey-Papafio. 1980. Cell-mediated immunity in 
herpes simplex virus-infected mice: induction,  characterization and antiviral effects 
of delayed type hypersensitivity. J. Gen.  Virol.  48:351. 
39.  Shand,  F.  L., and F.  Y. Liew.  1980.  Differential sensitivity to cyclophosphamide of 
helper T  cells for humoral responses and suppressor T  cells for delayed-type hyper- 
sensitivity. Eur. J. Immunol.  10:480. 
40.  Howard, J.  G.,  and  F.  L.  Shand.  1979.  Nature  of drug induced  B cell  tolerance. 
lmmunol. Rev. 43:43. 
41.  Merigan,  T.  C.,  and  D.  A.  Stevens.  1971.  Viral  infections in  man associated with 
acquired immunological deficiency states. Fed. Proc.  30:1858. 
42.  Nash, A. A., and P. Wildy.  1983. Immunity in relation to the pathogenesis of herpes 
simplex virus. In Human Immunity to Viruses. F. A. Ennis, editor. Academic Press, 
New York. 179-192. 
43.  Holder, A. A., and R. R. Freeman.  1981.  Immunisation against blood-stage rodent 
malaria using purified parasite antigens. Nature (Lond.). 294:361. 
44.  Russell,  S.  M.,  and  F.  Y.  Liew.  1979.  T  cells primed by influenza virion  internal 
components  can  cooperate  in  the  antibody  response  to  haemagglutinin.  Nature 
(Lond.). 280:147. 
45.  Russell,  S.  M.,  and  F.  Y.  Liew.  1980.  Cell  cooperation  in  antibody  responses  to 
influenza virus I. Priming of helper T  cells by internal  components of the virion. 
Eur. J. Immunol.  10:791. 
46.  Zinkernagel,  R.  M.,  and  P.  C.  Doherty.  1979.  MHC-restricted  cytotoxic T  cells: 
studies on the biological role of polymorphic major transplantation antigens deter- 
mining  T-cell  restriction-specificity,  function,  and  responsiveness.  Adv.  Immunol. 
27:52. 
47.  Anderson, W. A., and Kilbourne, E.  D.  1961. A herpes simplex skin test diagnostic 
antigen of low protein content from cell culture fluid. J. Invest. Dermatol.  37:25. 
48.  Lausch,  R., j.  Swyers, and  H.  Kaufman.  1966.  Delayed hypersensitivity to herpes 
simplex virus in the guinea-pig. J. lmmunol.  96:981. 
49.  Ashman, R. B., and A. Mullbacher.  1979. A T-belper cell for anti-viral cytotoxic T- 
cell responses. J. Exp. Med.  150:1277. 